For that slowly-ending reign of terror, I am sorry. But this is a story of perserverance, even in the face of uncertainty about jobs, and various other executive-officer inflicted adversities. The science team from legacy Organon ought to take a victory lap, here -- as its fluralaner oral tablet (proposed to be branded as BravectoTM) for dogs is very near EU market introduction now. Well done!
Here's a bit of the EIN Newsdesk press release feed, out of Merck EU:
. . . .MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).
The active substance of BRAVECTO, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. The benefits of BRAVECTO are its efficacy in the treatment of flea and tick infestations in dogs. The most common side effects are mild and transient gastrointestinal effects. . . .
So many, many things that Fred Hassan has mismanaged, apparently with complete impunity (he's off doing the same now at B + L. Ugh.). So it goes. [Since one side effect of the tablet is intermittent gas -- perhaps any puppy dosed with Bravecto, and out on a walk near Mr. Hassan, ought to aim its hind-parts in Mr. Hassan's general direction!] Seriously, well done, again, all of you at MSD Animal Health!
No comments:
Post a Comment